Skip to main content
MaaT Pharma logo

MaaT Pharma — Investor Relations & Filings

Ticker · MAAT ISIN · FR0012634822 LEI · 969500CQQB6XUNW6CN97 PA Professional, scientific and technical activities
Open in API
Filings indexed 347 across all filing types
Latest filing 2026-05-26 Earnings Release
Country FR France
Listing PA MAAT

About MaaT Pharma

https://www.maatpharma.com/

MaaT Pharma is a clinical-stage biotechnology company specializing in the development of microbiome-based therapeutics. The company's primary focus is on oncology, aiming to improve survival outcomes for cancer patients by modulating the immune system through the gut microbiome. It develops Microbiome Ecosystem Therapies (MET) designed to restore gut microbiome symbiosis. The company's pipeline includes product candidates for treating complications in patients with blood cancers and solid tumors, with its lead candidate, MaaT013, in late-stage development for acute Graft-versus-Host Disease (aGvHD). MaaT Pharma utilizes an AI-powered platform for drug development and has its own cGMP manufacturing capabilities.

Recent filings

Filing Released Lang Actions
Inside Information / Other news releases
Earnings Release Classification · 92% confidence The document is a press release providing key financial results (revenues, cash position) for Q1 2026 along with a business update and pipeline highlights. It presents initial quarterly financial figures and guidance but does not include full financial statements or detailed analysis. This matches the definition of an Earnings Release (ER). Q1 2026
2026-05-26 English
Informations privilégiées / Autres communiqués
Earnings Release Classification · 90% confidence The document is a press release (“Communiqué de Presse”) summarizing MaaT Pharma’s first quarter 2026 financial results (revenue, cash position, key highlights) and business updates. It provides initial quarterly results rather than the full interim financial statements, matching the definition of an Earnings Release (ER). Q1 2026
2026-05-26 French
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 85% confidence The document is a corporate press release updating on the EMA CHMP review and regulatory status of a drug application. It does not contain any financial statements or details of an annual or interim report, nor is it an earnings release, board change, dividend notice, or other specific category. It is a general regulatory and corporate announcement, so it best fits the fallback category "Regulatory Filings (RNS)."
2026-05-20 French
Inside Information / Other news releases
Regulatory Filings Classification · 85% confidence The document is a corporate press release providing an update on the regulatory review (EMA/CHMP) of a drug application and related cash management measures. It does not contain financial statements, earnings metrics, board changes, share transactions, or request shareholder votes. It is a general corporate/regulatory announcement that does not fit a specific report category, making the fallback Regulatory Filings (RNS) the appropriate classification.
2026-05-20 English
Informations privilégiées / Autres communiqués
Regulatory Filings Classification · 90% confidence The document is a press release announcing the convocation and logistical details of the company’s 2026 Annual General Meeting (AGM), together with its forward financial calendar. It does not contain actual AGM materials (presentations or resolutions), nor detailed proxy statements or voting results, and it is not a financial report. Rather, it is a general regulatory announcement to satisfy listing requirements. Therefore it falls under the general Regulatory Filings category (RNS).
2026-05-11 French
Inside Information / Other news releases
Proxy Solicitation & Information Statement Classification · 82% confidence The document is a press release notifying shareholders of the upcoming Annual General Meeting, detailing the convening notice, agenda, draft resolutions, and how to access proxy materials. It is not the AGM presentation itself nor the results, but rather the formal proxy solicitation/information statement sent to shareholders ahead of voting. Therefore, it falls under "Proxy Solicitation & Information Statement (PSI)."
2026-05-11 English

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.